創世紀(300083.SZ):擬收購控股子公司深圳創世紀的少數股東股權 明起停牌
格隆匯9月15日丨創世紀(300083.SZ)公佈,公司正在籌劃發行股份購買資產事項,因有關事項尚存在不確定性,經公司向深圳證券交易所申請,公司股票自2021年9月16日開市時起開始停牌。
公司擬發行股份購買控股子公司深圳市創世紀機械有限公司(“深圳創世紀”)的少數股東股權;同時,擬向不超過35名符合中國證監會規定的合格投資者以向特定對象發行股份方式募集配套資金,募集配套資金比例不超過擬購買資產交易價格100%,募集配套資金擬發行的股份數量不超過此次發行前上市公司總股本的30.00%。
此次發行股份購買資產完成後,深圳創世紀將成為公司的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.